An integrated molecular analysis of lung adenocarcinomas identifies potential therapeutic targets among TTF1-negative tumors, including DNA Repair Proteins and Nrf2

Clinical Cancer Research

Volumn 21, Issue 15, 2015, Pages 3480-3491

  Cardnell, Robert J G ^a   Behrens, Carmen ^a   Diao, Lixia ^a   Fan, You Hong ^a   Tang, Ximing ^a   Tong, Pan ^a   Minna, John D ^b   Mills, Gordon B ^a   Heymach, John V ^a   Wistuba, Ignacio I ^a   Wang, Jing ^a   Byers, Lauren A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 CARBAMOYL 6 (2,4 DIFLUOROPHENYL) 2 PYRIDINYL] 1 (2,6 DIFLUOROPHENYL)UREA; AXITINIB; AZD 8055; B RAF KINASE; CHECKPOINT KINASE 1; CYTARABINE; DACTOLISIB; DNA REPAIR PROTEIN; GD 0941; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN INHIBITOR; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; VELIPARIB; BRAF PROTEIN, HUMAN; DNA BINDING PROTEIN; KEAP1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; SIGNAL PEPTIDE; TTF1 PROTEIN, HUMAN;

ARTICLE; CANCER CELL LINE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA REPAIR; DRUG RESPONSE; DRUG TARGETING; FEMALE; GENE EXPRESSION; GENE MUTATION; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOLECULAR DIAGNOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; SIGNAL TRANSDUCTION; SQUAMOUS CELL LUNG CARCINOMA; ADENOCARCINOMA; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY;

ADENOCARCINOMA; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; LUNG NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; MUTATION; NF-E2-RELATED FACTOR 2; PROTEOMICS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION;

EID: 84942877422     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3286     Document Type: Article

References (53)

1. Bingle CD. Thyroid transcription factor-1. Int J Biochem Cell Biol 1997;29:1471-3.
2. Yamaguchi T, Hosono Y, Yanagisawa K, Takahashi T. NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression. Cancer Cell 2013;23:718-23.
3. Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, et al. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res 2011;17: 2434-43.
4. Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, et al. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer 2012;118:2889-99.
5. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006;24:1679-88.
6. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005;29:633-9.
7. Yoshida A, Tsuta K, Watanabe S, Sekine I, Fukayama M, Tsuda H, et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 2011; 72:309-15.
8. Vincenten J, Smit EF, Vos W, Grunberg K, Postmus PE, Heideman DA, et al. Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small cell lung cancer. J Thorac Oncol 2012;7:1522-7.
9. Shanzhi W, Yiping H, Ling H, Jianming Z, Qiang L. The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas. PLoS ONE 2014;9:e95479.
10. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2013; 19:279-90.
11. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, et al. Proteomic profiling identifies dysregulated pathways in small-cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012;2:798-811.
12. The Cancer Genome Atlas Research N. Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50.
13. Hu J, He X, Baggerly KA, Coombes KR, Hennessy BT, Mills GB. Non-parametric quantification of protein lysate arrays. Bioinformatics 2007; 23:1986-94.
14. Neeley ES, Baggerly KA, Kornblau SM. Surface adjustment of reverse phase protein arrays using positive control spots. Cancer Inform 2012; 11:77-86.
15. Tang H, Xiao G, Behrens C, Schiller J, Allen J, Chow CW, et al. A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res 2013;19:1577-86.
16. Solis LM, Raso MG, Kalhor N, Behrens C, Wistuba II, Moran CA. Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases. Am J Clin Pathol 2010;133:133-40.
17. Tang X, Shigematsu H, Bekele BN, Roth JA, Minna JD, Hong WK, et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 2005;65:7568-72.
18. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
19. The results shown here are in whole or part based upon data generated by the TCGA Research Network: Available from: http://cancergenome.nih.gov/.
20. Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, et al. Proteomic markers of DNA repair and PI3K pathway activation predict responsetothe PARP inhibitor BMN 673 in small-cell lung cancer. Clin Cancer Res 2013;19:6322-8.
21. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 2013;41: D955-61.
22. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
23. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics 2010;6:129-51.
24. Whitsett JA, Haitchi HM, Maeda Y. Intersections between pulmonary development and disease. Am J Respir Crit Care Med 2011;184: 401-6.
25. McDonald JM, Pelloski CE, Ledoux A, Sun M, Raso G, Komaki R, et al. Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res 2008;14:7832-7.
26. Gazdar AF. Activating and resistance mutations of EGFR in non-small cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009;28 Suppl 1:S24-31.
27. Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013;8:45-51.
28. Yousem SA, Nikiforova M, Nikiforov Y. The histopathology of BRAF-V600E-mutated lung adenocarcinoma. Am J Surg Pathol 2008;32: 1317-21.
29. Gautschi O, Pauli C, Strobel K, Hirschmann A, Printzen G, Aebi S, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 2012;7:e23-4.
30. Planchard D, Mazieres J, Riely GJ. Interim results of phase II study BRF113982 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients. J Clin Oncol, 2013; (Suppl; abstr 8009):31.
31. Available from: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#nscl.
32. Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 2010;16: 3743-53.
33. Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 2013;27:2179-91.
34. Al-Khalaf HH, Colak D, Al-Saif M, Al-Bakheet A, Hendrayani SF, Al-Yousef N, et al. p16(INK4a) positively regulates cyclin D1 and E2F1 through negative control of AUF1. PLoS ONE 2011;6:e21111.
35. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Mycregulated microRNAs modulate E2F1 expression. Nature 2005;435: 839-43.
36. Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K, et al. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non-small cell lung cancer. Clin Cancer Res 2007;13:6938-46.
37. Sun JM, Han J, Ahn JS, Park K, Ahn MJ. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 2011;6:1392-9.
38. Hou J, Lambers M, den Hamer B, den Bakker MA, Hoogsteden HC, Grosveld F, et al. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy. J Thorac Oncol 2012;7: 105-14.
39. Chen S, Xu Y, Chen Y, Li X, Mou W, Wang L, et al. SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells. PLoS ONE 2012;7:e36326.
40. Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, et al. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS ONE 2010;5:e9112.
41. Justilien V, Walsh MP, Ali SA, Thompson EA, Murray NR, Fields AP. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell 2014;25:139-51.
42. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012; 44:1111-6.
43. Freier K, Knoepfle K, Flechtenmacher C, Pungs S, Devens F, Toedt G, et al. Recurrent copy number gain of transcription factor SOX2 and corresponding high protein expression in oral squamous cell carcinoma. Genes Chromosomes Cancer 2010;49:9-16.
44. Gil del Alcazar CR, Hardebeck MC, Mukherjee B, Tomimatsu N, Gao X, Yan J, et al. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res 2014;20:1235-48.
45. Gronberg BH, Lund-Iversen M, Strom EH, Brustugun OT, Scott H. Associations between TS, TTF-1, FR-alpha, FPGS, and overall survival in patients with advanced non-small cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy. J Thorac Oncol 2013;8:1255-64.
46. Boggaram V. Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. Clin Sci 2009;116:27-35.
47. Zscheppang K, Giese U, Hoenzke S, Wiegel D, Dammann CE. ErbB4 is an upstream regulator of TTF-1 fetal mouse lung type II cell development in vitro. Biochim Biophys Acta 2013;1833:2690-702.
48. Alroy I, Soussan L, Seger R, Yarden Y. Neu differentiation factor stimulates phosphorylation and activation of the Sp1 transcription factor. Mol Cell Biol 1999;19:1961-72.
49. Arlt A, Sebens S, Krebs S, Geismann C, Grossmann M, Kruse ML, et al. Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene 2013;32:4825-35.
50. Limonciel A, Jennings P. A review of the evidence that ochratoxin A is an Nrf2 inhibitor: implications for nephrotoxicity and renal carcinogenicity. Toxins 2014;6:371-9.
51. Wu T, Harder BG, Wong PK, Lang JE, Zhang DD. Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy? Mol Carcinog. 2014 Aug 23. [Epub ahead of print].
52. Volonte D, Liu Z, Musille PM, Stoppani E, Wakabayashi N, Di YP, et al. Inhibition of nuclear factor-erythroid 2-related factor (Nrf2) by caveolin-1 promotes stress-induced premature senescence. Mol Biol Cell 2013;24: 1852-62.
53. Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008;283:17969-78.